Related Experiment Video
Updated: Jun 13, 2025
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
Genetics, Pathophysiology, and Current Challenges in Von Hippel-Lindau Disease Therapeutics
Laura Gómez-Virgilio1, Mireya Velazquez-Paniagua1, Lucero Cuazozon-Ferrer1,2
1Laboratory of Cellular Reprogramming, Department of Physiology, Facultad de Medicina, Universidad Nacional Autónoma de México, Av. Universidad No. 3000, Coyoacan CDMX 04510, Mexico.
Abstract:
This review article focuses on von Hippel-Lindau (VHL) disease, a rare genetic disorder characterized by the development of tumors and cysts throughout the body. It discusses the following aspects of the disease.
Genetics:
VHL disease is caused by mutations in the VHL tumor suppressor gene located on chromosome 3. These mutations can be inherited or occur spontaneously. This article details the different types of mutations and their associated clinical features.
Pathophysiology:
The underlying cause of VHL disease is the loss of function of the VHL protein (pVHL). This protein normally regulates hypoxia-inducible factors (HIFs), which are involved in cell growth and survival. When pVHL is dysfunctional, HIF levels become elevated, leading to uncontrolled cell growth and tumor formation.
Clinical Manifestations:
VHL disease can affect various organs, including the brain, spinal cord, retina, kidneys, pancreas, and adrenal glands. Symptoms depend on the location and size of the tumors.
Diagnosis:
Diagnosis of VHL disease involves a combination of clinical criteria, imaging studies, and genetic testing.
Treatment:
Treatment options for VHL disease depend on the type and location of the tumors. Surgery is the mainstay of treatment, but other options like radiation therapy may also be used.
Challenges:
This article highlights the challenges in VHL disease management, including the lack of effective therapies for some tumor types and the need for better methods to monitor disease progression. In conclusion, we emphasize the importance of ongoing research to develop new and improved treatments for VHL disease.
Insights
Von Hippel-Lindau (VHL) disease is a genetic disorder causing tumors due to VHL gene mutations. Management is challenging, requiring ongoing research for better therapies and monitoring.
Area of Science:
- Genetics and Molecular Biology
- Oncology
- Rare Diseases
Background:
- Von Hippel-Lindau (VHL) disease stems from mutations in the VHL tumor suppressor gene on chromosome 3.
- These mutations, either inherited or spontaneous, lead to a loss of function in the VHL protein (pVHL).
- pVHL normally regulates hypoxia-inducible factors (HIFs), crucial for cell growth and survival.
Purpose of the Study:
- To provide a comprehensive review of Von Hippel-Lindau (VHL) disease.
- To detail the genetic basis, pathophysiology, clinical manifestations, diagnosis, and treatment of VHL disease.
- To highlight current challenges and future research directions in VHL disease management.
Main Methods:
- Review of existing literature on VHL disease.
- Analysis of genetic mutations and their impact on pVHL function.
- Compilation of information on clinical presentation, diagnostic approaches, and therapeutic strategies.
Main Results:
- VHL disease affects multiple organs, including the brain, spinal cord, retina, kidneys, pancreas, and adrenal glands.
- Tumor development and cyst formation are characteristic manifestations.
- Symptoms vary based on tumor location and size.
Conclusions:
- Diagnosis relies on clinical criteria, imaging, and genetic testing.
- Treatment primarily involves surgery, with radiation therapy as an option.
- Effective therapies for certain tumor types are lacking, emphasizing the need for improved monitoring and research into novel treatments.
More Related Videos
08:26A Comprehensive Procedure to Evaluate the In Vitro Performance of the Putative Hemangioblastoma Neovascularization Using the Spheroid Sprouting Assay
Published on: April 12, 2018
07:04Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Published on: February 4, 2021
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
01:22Lysosomal Hydrolases
01:22iPS Cell Differentiation
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
01:10Mechanism of Angiogenesis
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...